Clostridium difficile: improving the prevention paradigm in healthcare settings

References

• CDC. Available from: www.cdc.gov/HAI/organisms/cdiff/Cdiff_infect.htm [Last accessed 19 January 2014]
   Google Scholar
• Hall IC, O’Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe. Bacillus difficilis. Am J Dis Child 1935;49:390-402
   Google Scholar
• Bartlett JG, Chang TW, Gurwith M, Gorbach SL. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978;298:531-4
   PubMed Web of Science ®Google Scholar
• Young VB, Hanna PC. Overlapping roles for toxins in C. difficile infection. J Infect Dis 2014;209:9-11
   PubMed Web of Science ®Google Scholar
• CDC. Available from: www.cdc.gov/VitalSigns/Hai/StoppingCdifficile/
   Google Scholar
• Lucado J, Gould C, Elixhauser A. Clostridium difficile Infections (CDI) in hospital stays, 2009. HCUP Statistical Brief #124. Agency for Healthcare Research and Quality. 2012. Available from: www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf [Last accessed 24 January 2014]
   Google Scholar
• Tyler JA, Fox JP, Desai MM, et al. Outcomes and costs associated with robotic colectomy in the minimally invasive era. Dis Colon Rectum 2013;56(4):458-66
   PubMed Web of Science ®Google Scholar
• Jury LA, Sitzlar B, Kundrapu S, et al. Outpatient healthcare settings and transmission of Clostridium difficile. PLoS One 2013;8(7):e70175
   PubMed Web of Science ®Google Scholar
• Goldstein EJ. Anaerobic Bacteremia. Clin Infect Dis 1996;23(Suppl 1):S97-101
   PubMed Web of Science ®Google Scholar
• CDC. Available from: www.cdc.gov
   Google Scholar
• McDonald LC, Kilgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353(23):2433-41
   PubMed Web of Science ®Google Scholar
• CDC. Available from: www.cdc.gov/NCIDOD/DHQP/pdf/guidelines/Isolation2007.pdf
   Google Scholar
• Gerding DN, Muto CA, Owens RC. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S43-9
   PubMed Web of Science ®Google Scholar
• Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-70
   PubMed Web of Science ®Google Scholar
• Debast SB, van Leengoed LA, Goorhuis A, et al. Clostridium difficile PCR ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans. Environ Microbiol 2009;11:505-11
   PubMed Web of Science ®Google Scholar
• Bouttier S, Barc MC, Felix B, et al. Clostridium difficile in ground meat, France. Emerg Infect Dis 2010;16(4):733-5
   PubMed Web of Science ®Google Scholar
• Songer JG, Trinh HT, Killgore GE, et al. Clostridium difficile in retail meat products. Emerg Infect Dis 2009;15(5):819-21
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55
   PubMed Web of Science ®Google Scholar
• Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40(1):1-15
   PubMed Web of Science ®Google Scholar
• Specter M. Germs are us. The New Yorker. 2012. Available from: www.newyorker.com/reporting/2012/10/22/121022fa_fact_specter?currentPage=all
   Google Scholar
• Rousseau C, Poilane I, De Pontual L, et al. Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis 2012;55(9):1209-15
   PubMed Web of Science ®Google Scholar
• Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota as revealed by deep 16S r RNA sequencing. PLoS Biol 2008;6(11):e280
   PubMed Web of Science ®Google Scholar
• Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197(3):435-8
   PubMed Web of Science ®Google Scholar
• Pathak R, Enuh HA, Patel A, Wickremesinghe P. Treatment of relapsing Clostridium difficile infection using fecal microbiota transplantation. Clin Exp Gastroenterol 2013;7:1-6
   PubMedGoogle Scholar
• Goorhuis A, Debast SB, Dutilh JC, et al. Type-specific risk factors and outcome in an outbreak with 2 different CDI types simultaneously in 1 hospital. Clin Infect Dis 2011;53(9):860-9
   PubMed Web of Science ®Google Scholar
• Debast SB, Vaessen N, Choudry A, et al. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect 2009;15:427-34
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Konstantelias AA, Loizidis G, et al. Risk factors for development of CDI infection due to BI/NAP1/027 strain: a meta-analysis. Int J Infect Dis 2012;16(11):e768-73
   PubMed Web of Science ®Google Scholar
• Gui J, Mustachio LM, Su DM, Craig RW. Thymus size and age-related thymic involution: early programming, sexual dimorphism, progenitors and stoma. Aging Dis 2012;3(3):280-90
   PubMed Web of Science ®Google Scholar
• Leung J, Burke B, Ford D, et al. Possible association between obesity and Clostridium difficile infection. Emerg Infect Dis 2013;19(11):1791-8
   PubMed Web of Science ®Google Scholar
• Cox LM, Blaser MJ. Pathways in microbe-induced obesity. Cell Metab 2013;17(6):883-94
   PubMed Web of Science ®Google Scholar
• Bishara J, Farah R, Mograbi J, et al. Obesity as a risk factor for Clostridium difficile infection. Clin Infect Dis 2013;57:489-93
   PubMed Web of Science ®Google Scholar
• Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:345-51
   PubMed Web of Science ®Google Scholar
• Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci USA 2012;109:594-9
   PubMed Web of Science ®Google Scholar
• Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:339-44
   PubMed Web of Science ®Google Scholar
• Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol 2010;16:4892-904
   PubMed Web of Science ®Google Scholar
• Li E, Hamm CM, Gulati AS, et al. Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition. PLoS One 2012;7:e26284
   PubMed Web of Science ®Google Scholar
• Fainstein V, Bodney GP, Fekety R. Relapsing pseudomenbranous colitis associated with cancer chemotherapy. J Infect Dis 1981;143(6):865
   PubMed Web of Science ®Google Scholar
• Chopra T, Alangaden GJ, Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 2010;8(10):1113-19
   PubMed Web of Science ®Google Scholar
• Vollaard EJ, Clasener HA. Colonization resistance. Antimicrob Agents Chemother 1994;38(3):409-14
   PubMed Web of Science ®Google Scholar
• Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004;39(2):219-26
   PubMed Web of Science ®Google Scholar
• Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis 1993;16(Suppl 4):S214-18
   PubMed Web of Science ®Google Scholar
• Mai V, Braden CR, Heckendorf J, et al. Monitoring of stool microbiota in subjects with diarrhea indicates distortions in composition. J Clin Microbiol 2006;44(12):4550-2
   PubMed Web of Science ®Google Scholar
• Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in composition of fecal microbiota. J Clin Microbiol 2004;42(3):1203-6
   PubMed Web of Science ®Google Scholar
• Durand T, Lalande V, Petit JC, et al. Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile. Microb Ecol 2008;56(3):395-402
   PubMed Web of Science ®Google Scholar
• Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197:435-8
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346(5):334-9
   PubMed Web of Science ®Google Scholar
• Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-34
   PubMed Web of Science ®Google Scholar
• Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26(3):273-80
   PubMed Web of Science ®Google Scholar
• Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353(23):2442-9
   PubMed Web of Science ®Google Scholar
• Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile–associated diarrhea and colitis in adults: a prospective case-controlled epidemiologic study. Arch Intern Med 1986;146:95-100
   PubMed Web of Science ®Google Scholar
• Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile–associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol 1991;12:345-8
   PubMed Web of Science ®Google Scholar
• Chang VT, Nelson K. The role of physical proximity in nosocomial diarrhea. Clin Infect Dis 2000;31:717-22
   PubMed Web of Science ®Google Scholar
• Nelson DE, Auerbach SB, Baltch AL, et al. Epidemic Clostridium difficile–associated diarrhea: role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol 1994;15:88-94
   PubMed Web of Science ®Google Scholar
• Pultz NJ, Donskey CJ. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother 2005;49:3529-32
   PubMed Web of Science ®Google Scholar
• Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013;68(9):1951-61
   PubMed Web of Science ®Google Scholar
• Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366(9491):1079-84
   PubMed Web of Science ®Google Scholar
• Søes L, Mølbak K, Strøbaek S, et al. The emergence of Clostridium difficile ribotype 027 in Denmark--a possible link with the increased consumption of fluoroquinolones and cephalosporins? Euro Surveill 2009;14:15
   PubMedGoogle Scholar
• McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353(23):2433-41
   PubMed Web of Science ®Google Scholar
• Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006;166(22):2518-24
   PubMedGoogle Scholar
• Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974;81(4):429-33
   PubMed Web of Science ®Google Scholar
• Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341(22):1645-51
   PubMed Web of Science ®Google Scholar
• Pear SM, Williamson TH, Bettin KM, et al. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120(4):272-7
   PubMed Web of Science ®Google Scholar
• Sambol SP, Merrigan MM, Tang JK, et al. Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 2002;186:1781-9
   PubMed Web of Science ®Google Scholar
• Larson HE, Borriello SP. Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters. Antimicrob Agents Chemother 1990;34:1348-53
   PubMed Web of Science ®Google Scholar
• Pear SM, Williamson TH, Bettin KM, et al. Decrease in nosocomial Clostridium difficile–associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120:272-7
   PubMed Web of Science ®Google Scholar
• Climo MW, Israel DS, Wong ES, et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998;128(12 Pt 1):989-95
   PubMed Web of Science ®Google Scholar
• Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171(5):466-72
   PubMed Web of Science ®Google Scholar
• Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile -associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41(9):1254-60
   PubMed Web of Science ®Google Scholar
• McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9(6):730-3
   PubMed Web of Science ®Google Scholar
• Bradford PA, Weaver-Sands T, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41(Suppl 5):S315-32
   PubMed Web of Science ®Google Scholar
• Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41(Suppl 5):S303-14
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43:738-44
   PubMed Web of Science ®Google Scholar
• Edlund C, Nord CE. In vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000;6:158-63
   Web of Science ®Google Scholar
• Norén T, Alriksson I, Åkerlund T, et al. In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993–2007 in Sweden. Clin Microbiol Infec 2010;16:1104-10
   PubMed Web of Science ®Google Scholar
• Freeman J, Wilcox MH. Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2001;47:244-6
   PubMed Web of Science ®Google Scholar
• Bourgault AM, Lamothe F, Loo VG, Poirier L; CDAD-CSI Study Group. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada. Antimicrob Agents Chemother 2006;50:3473-5
   PubMed Web of Science ®Google Scholar
• Garneau JR, Valiquette L, Fortier LC. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis 2014;14(1):29
   PubMed Web of Science ®Google Scholar
• Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006;58(5):1062-5
   PubMed Web of Science ®Google Scholar
• Jump RL, Li Y, Pultz MJ, et al. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother 2011;55(2):546-9
   PubMed Web of Science ®Google Scholar
• Freeman J, Baines SD, Wilcox MH. Comparison of the efficacy of ramoplanin vs vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005;56:717-25
   PubMed Web of Science ®Google Scholar
• Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009;48(12):1732-5
   PubMed Web of Science ®Google Scholar
• Joshi N, Miller DQ. Doxycycline revisited. Arch Intern Med 1997;157:1421-8
   PubMedGoogle Scholar
• Robbins M, Marais R, Felmingham D, Ridgway GL. The in-vitro activity of doxycycline and minocycline against anaerobic bacteria. J Antimicrob Chemother 1987;20:379-82
   PubMed Web of Science ®Google Scholar
• Hirschhorn LR, Trnka Y, Onderdonk A, et al. Epidemiology of community-acquired Clostridium difficile associated diarrhea. J Infect Dis 1994;169:127-33
   PubMed Web of Science ®Google Scholar
• Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis 2012;55(5):615-20
   PubMed Web of Science ®Google Scholar
• Baxter R, Ray G, Fireman B. Case-Control study of antibiotic use and subsequent Clostridium difficile–associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008;29:44-50
   PubMed Web of Science ®Google Scholar
• Piacenti FJ, Leuthner KD. Antimicrobial stewardship and clostridium difficile-associated diarrhea. J Pharm Pract 2013;26(5):506-13
   PubMedGoogle Scholar
• Davey P, Brown E, Fenelon L, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005;CD003543
   PubMed Web of Science ®Google Scholar
• Valiquette L, Cossette B, Garant MP, et al. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007;45(Suppl 2):S112-21
   PubMed Web of Science ®Google Scholar
• Pear SM, Williamson TH, Bettin KM, et al. Decrease in nosocomial Clostridium difficile–associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120:272-7
   PubMed Web of Science ®Google Scholar
• Climo MW, Israel DS, Wong ES, et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile–associated diarrhea and cost. Ann Intern Med 1998;128(12 pt 1):989-95
   PubMed Web of Science ®Google Scholar
• Clindamycin formulary restriction lowers costs, antimicrobial resistance. Am J Health Syst Pharm 1998;55(15):1552
   PubMed Web of Science ®Google Scholar
• Dancer SJ, Kirkpatrick P, Corcoran DS, et al. Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum beta-lactamase-producing coliforms and methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2013;41(2):137-42
   PubMed Web of Science ®Google Scholar
• Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38(5):640-5
   PubMed Web of Science ®Google Scholar
• Aldeyab MA, Kearney MP, Scott MG, et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012;67(12):2988-96
   PubMed Web of Science ®Google Scholar
• Carling P, Fung T, Killion A, et al. Favorable impact of multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003;24(9):699-706
   PubMed Web of Science ®Google Scholar
• Dancer SJ, Kirkpatrick P, Corcoran DS, et al. Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum β-lactamase-producing coliforms and methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2013;41(2):137-42
   PubMed Web of Science ®Google Scholar
• Fowler S, Webber A, Cooper BS, et al. Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series. J Antimicrob Chemother 2007;59(5):990-5
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF. Preventing Clostridium difficile infection in the intensive care unit. Crit Care Clin 2013;29(1):11-18
   PubMed Web of Science ®Google Scholar
• Gurian L, Ward TT, Katon RM. Possible foodborne transmission in a case of pseudomembranous colitis due to Clostridium difficile: influence of gastrointestinal secretions on Clostridium difficile infection. Gastroenterology 1982;83(2):465-9
   PubMed Web of Science ®Google Scholar
• Kaur S, Vaishnavi C, Prasad KK, et al. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol 2007;51(12):1209-14
   PubMed Web of Science ®Google Scholar
• Wilson KH, Sheagren JN, Freter R. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis 1985;151:355-61
   PubMed Web of Science ®Google Scholar
• Tasteyre A, Karjalainen T, Avesani V, et al. Phenotypic and genotypic diversity of the flagellin gene (fliC) among Clostridium difficile isolates from different serogroups. J Clin Microbiol 2000;38:3179-86
   PubMed Web of Science ®Google Scholar
• Seddon SV, Hemingway I, Borriello SP. Hydrolytic enzyme production by Clostridium difficile and its relationship to toxin production and virulence in the hamster model. J Med Microbiol 1990;31:169-74
   PubMed Web of Science ®Google Scholar
• Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39(1):54-9
   PubMed Web of Science ®Google Scholar
• Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol 2001;15(3):511-21
   PubMed Web of Science ®Google Scholar
• Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002;30(5):1118-22
   PubMed Web of Science ®Google Scholar
• Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors inhibitors effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000;14(Suppl 1):74-81
   PubMed Web of Science ®Google Scholar
• Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol 2000;22(2):357-72
   PubMed Web of Science ®Google Scholar
• Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile -associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012;107(7):1001-10
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS ONE 2012;7(12):e50836
   PubMed Web of Science ®Google Scholar
• Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107(7):1011-19
   PubMed Web of Science ®Google Scholar
• Leontiadis GI, Miller MA, Howden CW. How much do PPIs contribute to C. difficile infections? Am J Gastroenterol 2012;107(7):1020-1
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Abrams JA. Does confounding explain the association between PPIs and Clostridium difficile-related diarrhea? Am J Gastroenterol 2013;108(2):278-9
   PubMed Web of Science ®Google Scholar
• Chandra S, Agarwal D, Surana A. Risk of Clostridium difficile infection with acid-suppressive therapy; pitfalls in accurate estimation. Am J Gastroenterol 2013;108(2):277-8
   PubMed Web of Science ®Google Scholar
• King RN, Lager SL. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy. Pharmacotherapy 2011;31(7):642-8
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent clostridium difficile infection among inpatients. Am J Gastroenterol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs. Available from: www.fda.gov/drugs/drugsafety/ucm290510.htm#sa
   Google Scholar
• Moayyedi P, Leontiadis GI. Risks of proton pump inhibitor therapy. Nat Rev Gastroenterol Hepatol 2012;9(3):132-9
   PubMed Web of Science ®Google Scholar
• Cadle RM, Mansouri MD, Logan N, et al. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm 2007;64(22):2359-63
   PubMed Web of Science ®Google Scholar
• Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010;170(9):772-8
   PubMedGoogle Scholar
• Barletta JF, El-Ibiary SY, Davis LE, et al. Proton pump inhibitors and the risk for hospital-acquired clostridium difficile infection. Mayo Clin Proc 2013;88(10):1085-90
   PubMed Web of Science ®Google Scholar
• Sullivan A, Nord CE. Probiotics in human infections. J Antimicrob Chemother 2002;50(5):625-7
   PubMed Web of Science ®Google Scholar
• Gueimonde M, Salminen S. New methods for selecting and evaluating probiotics. Dig Liver Dis 2006;38(Suppl 2):S242-7
   PubMedGoogle Scholar
• Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect Dis 2009;9:237-44
   PubMed Web of Science ®Google Scholar
• Maziade PJ, Andriessen JA, Pereira P, et al. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 2013;29(10):1341-7
   PubMed Web of Science ®Google Scholar
• Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012;157:878-88
   PubMed Web of Science ®Google Scholar
• Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and metaanalysis. JAMA 2012;307(18):1959-69
   PubMed Web of Science ®Google Scholar
• Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile -associated diarrhea in adults and children. Cochrane Database Syst Rev 2013;5:CD006095
   PubMed Web of Science ®Google Scholar
• Hickson M, D’Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335(7610):80
   PubMed Web of Science ®Google Scholar
• Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol 2011;4(3):185-97
   PubMedGoogle Scholar
• Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med 2013;7(2):e56-67
   PubMedGoogle Scholar
• Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010;105:1636-41
   PubMed Web of Science ®Google Scholar
• Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004;7(1):59-62
   PubMed Web of Science ®Google Scholar
• Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, et al. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-55
   PubMed Web of Science ®Google Scholar
• Hempel S, Newberry S, Ruelaz A, et al. Safety of probiotics to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep) 2011(200):1-645
   PubMedGoogle Scholar
• Theodorakopoulou M, Perros E, Giamarellos-Bourboulis EJ, Dimopoulos G. Controversies in the management of the critically ill: the role of probiotics. Int J Antimicrob Agents 2013;42 Suppl:S41-4
   PubMed Web of Science ®Google Scholar
• Johnson S, Maziade PJ, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 2012;16(11):e786-92
   PubMed Web of Science ®Google Scholar
• Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62
   PubMed Web of Science ®Google Scholar
• Pothoulakis C. Pathogenesis of Clostridium difficile-associated diarrhoea. Eur J Gastroenterol Hepatol 1996;8:1041-7
   PubMed Web of Science ®Google Scholar
• Riegler M, Sedivy R, Pothoulakis C, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995;95:2004-11
   PubMed Web of Science ®Google Scholar
• Kyne L, Warner M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum level of IgG antibody against toxin A. N Engl J Med 2000;342(6):390-7
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 2001;357(9251):189-93
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006;145(10):758-64
   PubMed Web of Science ®Google Scholar
• Yang XQ, Zhao YG, Chen XQ, et al. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model. BMC Gastroenterol 2013;13:117
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001;69(2):988-95
   PubMed Web of Science ®Google Scholar
• Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003;71(3):1608-10
   PubMed Web of Science ®Google Scholar
• Study of different formulations of a clostridium difficile toxoid vaccine given at three different schedules in adults. Available from: www.clinicaltrials.gov/ct2/results?term=NCT01230957&Search=Search
   Google Scholar
• Study of a clostridium difficile toxoid vaccine (ACAM-CDIFF™) in subjects with clostridium difficile infection. Available from: www.clinicaltrials.gov/ct2/results?term=NCT00772343&Search=Search
   Google Scholar
• Cdiffense. Available from: www.cdiffense.org
   Google Scholar
• Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004;109(21 Suppl 1):II-42-8
   Web of Science ®Google Scholar
• Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-21
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118
   PubMed Web of Science ®Google Scholar
• Motzkus-Feagans CA, Pakyz A, Polk R, et al. Statin use and the risk of CDI in academic medical centres. Gut 2012;61(11):1538-42
   PubMed Web of Science ®Google Scholar
• Nseir W, Bishara J, Mograbi J, et al. Do statins protect against the development of CDI-associated diarrhoea? J Antimicrob Chemother 2013;68(8):1889-93
   PubMed Web of Science ®Google Scholar
• Park SW, Choi AR, Lee HJ, et al. The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther 2013;38(6):619-27
   PubMed Web of Science ®Google Scholar
• Naggie S, Miller BA, Zuzak KB, et al. A case-control study of community-associated CDI infection: no role for proton pump inhibitor. Am J Med 2011;124(3):276.e1-7
   Web of Science ®Google Scholar
• Dobesh PP, Klepser DG, McGuire TR, et al. Statins associated with a reduction in mortality in patients with sepsis. Pharmacotherapy 2009;29:621-30
   PubMed Web of Science ®Google Scholar
• McGuire T, Dobesh P, Klepser D, et al. Clinically important interaction between statin drugs and CDI toxin? Med Hypotheses 2009;73(6):1045-7
   PubMed Web of Science ®Google Scholar
• Sydnor ER, Perl T. Hospital epidemiology and infection control in acute care settings. Clin Microbiol Rev 2011;24(1):141-73
   PubMed Web of Science ®Google Scholar
• CDC. Type and duration of precautions recommended for selected infections and conditions, Appendix A. Available from: www.cdc.gov/hicpac/2007ip/2007ip_appenda.html
   Google Scholar
• Dubberke ER, Gerding DN. Rationale for hand hygiene recommendations after caring for a patient with Clostridium difficile Infection. a compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Fall 2011 Update
   Google Scholar
• Landelle C, Verachten M, Legrand P, et al. Contamination of healthcare workers’ hands with Clostridium difficile spores after caring for patients with C. difficile Infection. Infect Control Hosp Epidemiol 2014;35(1):10-15
   PubMed Web of Science ®Google Scholar
• Dumford DM, Nerandzic MM, Eckstein BC, Donskey CJ. What is on that keyboard? Detecting hidden environmental reservoirs of Clostidium difficile during an outbreak associated with North American pulsed-field gel electrophoresis type I strains. Am J Infect Control 2009;37(1):15-19
   PubMed Web of Science ®Google Scholar
• Available from: www.epa.gov/oppad001/chemregindex.htm
   Google Scholar
• Available from: www.bioquell.com/products/
   Google Scholar
• Passaretti CL, Otter J, Reich NG, et al. An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug resistant organisms. Clin Infect Dis 2013;56(1):27-35
   PubMed Web of Science ®Google Scholar
• Available from: http://singularityhub.com/2013/01/13/uv-light-emitting-robot-disinfects-hospital-rooms-in-minutes/
   Google Scholar
• Available from: www.timesunion.com/local/article/With-a-zap-germs-meet-their-match-3507541.php
   Google Scholar
• Stibich MS, Stachowiak J, Tanner B, et al. Evaluation of pulsed xenon ultraviolet room disinfection device for impact on hospital operations and microbial reduction. Infect Control Hosp Epidemiol 2011;32(3):286-8
   PubMed Web of Science ®Google Scholar
• Levin J, Riley LS, Parrish C, et al. The effect of portable pulsed xenon ultraviolet light after terminal cleaning on hospital-associated Clostridium difficile infection in a community hospital. Am J Infect Control 2013;41:746-8
   PubMed Web of Science ®Google Scholar
• Fornwalt L, Riddell B. Implementation of innovative pulsed xenon ultraviolet (PXUV) environmental cleaning in an acute care hospital. Risk Manag Healthc Policy 2014;7:25-8
   PubMedGoogle Scholar
• Barbut F, Yezli S, Mimoun M, et al. Reducing the Spread of Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus on a burns unit through the intervention of an infection control bundle. Burns 2012.39(3):395-403. Available from: http//dx.doi.org/10.1016/j.burns.2012.07.007
   Google Scholar
• APIC, Guide to the Elimination of Clostridium difficile in Healthcare Settings. 2008. Available from: www.apic.org/Resource_/EliminationGuideForm/5de5d1c1-316a-4b5e-b9b4-c3fbeac1b53e/File/APIC-Cdiff-Elimination-Guide.pdf
   Google Scholar
• Feazel LM, Malhotra A, Perecevich EN, et al. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother 2014;69:1748-54
   PubMed Web of Science ®Google Scholar
• Available from: www.isixsigma.com/implementation/change-management-implementation/preventing-conflicts-through-stakeholder-management/
   Google Scholar
• Miller BA. ICHE. 2011;32(4):387-90
   Google Scholar
• Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Infect Dis 2012;55(Suppl 2):S132-42
   Web of Science ®Google Scholar
• Dubberke ER, Carling P, Carrico R, et al. Strategies to prevent Clostridium. difficile infections in acute care hospitals: 2014 Update. Infect Control Hosp Epidemiol 2014;35(6):628-45
   PubMed Web of Science ®Google Scholar
• CDC. Available from: www.cdc.gov/HAI/organisms/cdiff/Cdiff_clinicians.html
   Google Scholar
• Pakyz AL, Jawahar R, Wang Q, Harpe SE. Medication risk factors associated with healthcare-associated Clostridium difficile infection: a multilevel model case-control study among 64 US academic medical centres. J Antimicrob Chemother 2014;69(4):1127-31
   PubMed Web of Science ®Google Scholar
• Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69(4):881-91
   PubMed Web of Science ®Google Scholar
• van der Kooi TI, Koningstein M, Lindemans A, et al. Antibiotic use and other risk factors at hospital level for outbreaks with Clostridium difficile PCR ribotype 027. J Med Microbiol 2008;57(Pt 6):709-16
   PubMed Web of Science ®Google Scholar
• Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile -associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008;29(1):44-50
   PubMed Web of Science ®Google Scholar
• Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother 2011;66(9):2168-74
   PubMed Web of Science ®Google Scholar
• Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-19
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infection. Am J Gastroenterol 2013;108:478-98
   PubMed Web of Science ®Google Scholar